We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

DIAGNOSTICA STAGO

Offers a complete system of hemostasis instrumentation and optimized reagent kits for research, as well as for routin... read more Featured Products: More products

Download Mobile App





STAGO sthemO and sthemE Product Ranges Make World Premiere

By LabMedica International staff writers
Posted on 24 May 2023
Print article
Image: Stago unveiled the sthemO 301 and 201 hemostasis analyzers at EuroMedlab 2023 (Photo courtesy of Stago)
Image: Stago unveiled the sthemO 301 and 201 hemostasis analyzers at EuroMedlab 2023 (Photo courtesy of Stago)

Diagnostica Stago (Asnières-sur-Seine, France) is unveiling its new coagulation line - the sthemO and sthemE product ranges - at WorldLab–EuroMedLab Roma 2023.

Leveraging its proficiency in hemostasis, Stago has diversified its product line to incorporate hematology, becoming a multi-specialist in these fields. The company's new "sthem" brand represents a significant leap towards next-generation Stago solutions. Drawing from over 60 years of partnership with coagulation professionals, Stago has introduced sthemO, a fresh line of hemostasis devices and reagents designed to fulfill the evolving demands of laboratories. The sthemO 301, the first analyzer in the sthemO hemostasis series, is a high-throughput, fully automated coagulation analyzer designed for medium to large laboratories and can be integrated into automated tracks. It offers the perfect combination of expertise, performance, and innovation. Also included in the new range of sthemO analyzers by Stago is the sthemO 201. This bench-top analyzer, suitable for smaller laboratories, offers the same level of efficiency and analytical performance as the sthemO 301. Its simplicity and versatility enable laboratories to concentrate on value-added tasks.

The sthemO analyzers are qualitative and/or quantitative automated hemostasis platforms for in vitro diagnostic use by clinical laboratory staff and are to be used with dedicated sthemO reagents and controls. The company has emphasized technological advancement, integrating an increasing number of features into its sthemO coagulation devices to simplify operations for laboratories and patients alike. The sthemO series incorporates immuno-chemiluminescence technology to provide superior analytical performance and an extensive range of tests. Additionally, Stago has developed a unique cuvette design, compatible with all embedded technologies, to provide a highly efficient, user-friendly system.

In order to optimize these two novel systems, Stago has also launched new eSolutions under the sthemE umbrella. The sthemE Manager is designed to facilitate data and information exchange between one or several in vitro diagnostic analyzers and laboratory information systems. This system, encompassing the sthemE Manager and one or more analyzers, is managed by authorized laboratory personnel. sthemE Manager is not intended for use with specific assays.

Related Links:
Diagnostica Stago

New
Gold Member
ZIKA Virus Test
ZIKA ELISA IgG
New
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Multi-Channel Pipettor
BioPette Plus
New
RNA Isolation Kits
RNeasy Plus Kits for RNA Isolation

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.